JP2022524997A - 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 - Google Patents

慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 Download PDF

Info

Publication number
JP2022524997A
JP2022524997A JP2021552624A JP2021552624A JP2022524997A JP 2022524997 A JP2022524997 A JP 2022524997A JP 2021552624 A JP2021552624 A JP 2021552624A JP 2021552624 A JP2021552624 A JP 2021552624A JP 2022524997 A JP2022524997 A JP 2022524997A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
jak1
pathway inhibitor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021552624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524997A5 (https=
Inventor
エル ショーブ，リチャード
オヘヤー，ケビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of JP2022524997A publication Critical patent/JP2022524997A/ja
Publication of JP2022524997A5 publication Critical patent/JP2022524997A5/ja
Priority to JP2025026650A priority Critical patent/JP2025087734A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021552624A 2019-03-05 2020-03-05 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 Pending JP2022524997A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025026650A JP2025087734A (ja) 2019-03-05 2025-02-21 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814085P 2019-03-05 2019-03-05
US62/814,085 2019-03-05
PCT/US2020/021088 WO2020181034A1 (en) 2019-03-05 2020-03-05 Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025026650A Division JP2025087734A (ja) 2019-03-05 2025-02-21 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤

Publications (2)

Publication Number Publication Date
JP2022524997A true JP2022524997A (ja) 2022-05-11
JP2022524997A5 JP2022524997A5 (https=) 2023-03-13

Family

ID=69941525

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552624A Pending JP2022524997A (ja) 2019-03-05 2020-03-05 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤
JP2025026650A Pending JP2025087734A (ja) 2019-03-05 2025-02-21 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025026650A Pending JP2025087734A (ja) 2019-03-05 2025-02-21 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤

Country Status (15)

Country Link
US (2) US11406640B2 (https=)
EP (2) EP4691567A3 (https=)
JP (2) JP2022524997A (https=)
KR (1) KR20210137087A (https=)
CN (1) CN114007621A (https=)
AU (1) AU2020232757B2 (https=)
CA (1) CA3132371A1 (https=)
EA (1) EA202192426A1 (https=)
IL (1) IL285999B2 (https=)
MA (1) MA55201A (https=)
MX (2) MX2021010545A (https=)
PH (1) PH12021552130A1 (https=)
SG (1) SG11202109563WA (https=)
UA (1) UA130579C2 (https=)
WO (1) WO2020181034A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3837258T3 (fi) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
UA127328C2 (uk) 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
CA3117969A1 (en) 2018-10-31 2020-05-07 Incyte Corporation Combination therapy for treatment of hematological diseases
WO2020181034A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
TW202237083A (zh) * 2021-01-11 2022-10-01 美商英塞特公司 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法
EP4359402B1 (en) 2021-06-25 2026-03-11 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
KR102952944B1 (ko) 2021-10-15 2026-04-14 주식회사 엘지에너지솔루션 용접봉 체결 방법 및 이에 의해 용접봉이 수직으로 체결된 용접 장치

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016527315A (ja) * 2013-08-07 2016-09-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ１阻害剤のための徐放性剤形

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US20070219223A1 (en) 2006-03-07 2007-09-20 Endacea, Inc. Compositions and methods for treating respiratory disorders
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
EP2684564A1 (en) 2008-04-17 2014-01-15 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
RU2711869C3 (ru) 2009-12-01 2022-02-02 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
HRP20250965T1 (hr) 2012-06-15 2025-10-10 Sun Pharmaceutical Industries, Inc. Deuterirani derivati ruksolitiniba
WO2014028756A1 (en) 2012-08-17 2014-02-20 Concert Pharmaceuticals, Inc. Deuterated baricitinib
TWI646099B (zh) 2012-11-01 2019-01-01 英塞特控股公司 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
HUE033587T2 (hu) 2013-05-17 2017-12-28 Incyte Corp Bipirazol-származékok mint JAK inhibitorok
AU2014339897A1 (en) * 2013-10-24 2016-04-21 Abbvie Inc. JAK1 selective inhibitor and uses thereof
KR20160136323A (ko) 2014-02-28 2016-11-29 인사이트 코포레이션 골수형성이상증후군 치료용 jak1 억제제
MA39987A (fr) 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
CN105294699B (zh) * 2015-12-04 2019-06-11 上海勋和医药科技有限公司 巴瑞替尼的制备方法
MX390005B (es) * 2016-10-03 2025-03-20 Hangzhou Highlightll Pharmaceutical Co Ltd Inhibidores selectivos de jak1 novedosos y usos de los mismos.
EP3327020A1 (en) * 2016-11-29 2018-05-30 Sandoz Ag Citrate salts of a janus kinase (jak) inhibitor
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
KR102925957B1 (ko) 2018-02-16 2026-02-11 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
CA3097025A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
CA3117969A1 (en) 2018-10-31 2020-05-07 Incyte Corporation Combination therapy for treatment of hematological diseases
JP7624922B2 (ja) 2018-12-19 2025-01-31 インサイト・コーポレイション 胃腸疾患の治療のためのｊａｋ１経路阻害剤
WO2020181034A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016527315A (ja) * 2013-08-07 2016-09-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ１阻害剤のための徐放性剤形

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHELLE SCHOETTLER; ET AL: "RUXOLITINIB IS AN EFFECTIVE STEROID SPARING AGENT IN CHILDREN WITH STEROID REFRACTORY /DEPENDENT BRO", BONE MARROW TRANSPLANTATION, vol. VOL:54, NR:7, JPN5022007022, 25 January 2019 (2019-01-25), GB, pages 1158 - 1160, ISSN: 0005442384 *

Also Published As

Publication number Publication date
EP3934651A1 (en) 2022-01-12
US11406640B2 (en) 2022-08-09
AU2020232757A1 (en) 2021-10-07
IL285999B1 (en) 2025-09-01
UA130579C2 (uk) 2026-03-25
WO2020181034A1 (en) 2020-09-10
JP2025087734A (ja) 2025-06-10
EP4691567A3 (en) 2026-04-29
KR20210137087A (ko) 2021-11-17
PH12021552130A1 (en) 2022-08-31
CN114007621A (zh) 2022-02-01
EP4691567A2 (en) 2026-02-11
US20200281931A1 (en) 2020-09-10
EA202192426A1 (ru) 2021-11-15
IL285999A (en) 2021-10-31
CA3132371A1 (en) 2020-09-10
AU2020232757B2 (en) 2025-09-11
IL285999B2 (en) 2026-01-01
US20220331325A1 (en) 2022-10-20
MX2024007081A (es) 2024-06-21
SG11202109563WA (en) 2021-09-29
MX2021010545A (es) 2021-11-17
US11896595B2 (en) 2024-02-13
MA55201A (fr) 2022-01-12

Similar Documents

Publication Publication Date Title
JP2022524997A (ja) 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤
US12336998B2 (en) JAK1 pathway inhibitors for the treatment of cytokine-related disorders
US20240293411A1 (en) Combination therapy comprising jak pathway inhibitor and rock inhibitor
EA044660B1 (ru) Ингибиторы путей jak1 для лечения хронической дисфункции аллотрансплантата легких
EA050167B1 (ru) Комбинированная терапия, включающая ингибитор пути jak и ингибитор rock
TW202438061A (zh) 用於治療氣喘之ｊａｋ１路徑抑制劑
CN117120055A (zh) 包含jak通路抑制剂和rock抑制剂的组合疗法
EA042956B1 (ru) Ингибиторы пути jak1, предназначенные для лечения связанных с цитокинами нарушений
EA050837B1 (ru) Ингибиторы пути jak1, предназначенные для лечения связанных с цитокинами нарушений

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022